Sonoma Pharmaceuticals Statistics
Sonoma Pharmaceuticals (O8Z) Stock Statistics & Valuation Metrics
Total Valuation
Sonoma Pharmaceuticals has a market cap or net worth of EUR 3.85M. The enterprise value is EUR 2.28M.
- Market Cap
- EUR 3.85M
- Enterprise Value
- EUR 2.28M
Share Statistics
Sonoma Pharmaceuticals has 5,061,593 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,061,593
- Owned by Insiders
- 6.99%
- Owned by Institutions
- 1.47%
Financial Efficiency
Sonoma Pharmaceuticals’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -24.05%.
- Return on Equity (ROE)
- -1.03
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -24.05%
- Return on Capital Employed (ROCE)
- -0.27
- Revenue Per Employee
- 1.95M
- Profits Per Employee
- -317.50K
- Employee Count
- 10
- Asset Turnover
- 1.40
- Inventory Turnover
- 3.32
Valuation Ratios
The current PE Ratio of Sonoma Pharmaceuticals is -0.91. Sonoma Pharmaceuticals’s PEG ratio is -0.01.
- PE Ratio
- -0.91
- PS Ratio
- 0.18
- PB Ratio
- 0.61
- Price to FCF
- -1.50
- Price to Operating Cash Flow
- -1.52
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Sonoma Pharmaceuticals had revenue of 19.53M and earned -3.17M in profits. Earnings per share was -1.89.
- Revenue
- 19.53M
- Gross Profit
- 7.42M
- Operating Income
- -2.46M
- Pretax Income
- -3.42M
- Net Income
- -3.17M
- EBITDA
- -2.32M
- Earnings Per Share (EPS)
- -1.89
Cash Flow
In the last 12 months, operating cash flow was -2.67M and capital expenditures -120,000, giving a free cash flow of -2.79M billion.
- Operating Cash Flow
- -2.67M
- Free Cash Flow
- -2.79M
- Free Cash Flow per Share
- -0.57
Dividends & Yields
Sonoma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -66.52%
- Earnings Yield
- -44.19%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 2.69
- 200-Day Moving Average
- 2.69
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Sonoma Pharmaceuticals upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Sonoma Pharmaceuticals as a current ratio of 2.50, with Debt / Equity ratio of 27.21%
- Current Ratio
- 2.50
- Quick Ratio
- 1.75
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.67
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Sonoma Pharmaceuticals has paid -244.00K in taxes.
- Income Tax
- -244.00K
- Effective Tax Rate
- 0.07
Enterprise Valuation
Sonoma Pharmaceuticals EV to EBITDA ratio is -0.20, with an EV/FCF ratio of -0.07.
- EV to Sales
- 0.01
- EV to EBITDA
- -0.20
- EV to Free Cash Flow
- -0.07
- EV to Operating Cash Flow
- -0.07
Balance Sheet
Sonoma Pharmaceuticals has EUR 4.61M in cash and marketable securities with EUR 602.00K in debt, giving a net cash position of EUR 4.01M billion.
- Cash & Marketable Securities
- EUR 4.61M
- Total Debt
- EUR 602.00K
- Net Cash
- EUR 4.01M
- Net Cash Per Share
- EUR 0.79
- Tangible Book Value Per Share
- EUR 1.35
Margins
Gross margin is 39.23%, with operating margin of -3.32%, and net profit margin of -7.65%.
- Gross Margin
- 39.23%
- Operating Margin
- -3.32%
- Pretax Margin
- -5.93%
- Net Profit Margin
- -7.65%
- EBITDA Margin
- -4.00%
- EBIT Margin
- -4.55%

